Bone morphogenetic proteins and their receptor signaling in prostate cancer

Histology and Histopathology

Volumn 22, Issue 10-12, 2007, Pages 1129-1147

  Ye, Lin ^a   Lewis Russell, J M ^a   Kyanaston, H G ^b   Jiang, W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Bone metastasis; Bone morphogenetic protein; Cancer biology; Prostate cancer

Indexed keywords

AURORA A KINASE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 10; BONE MORPHOGENETIC PROTEIN 12; BONE MORPHOGENETIC PROTEIN 15; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 8A; BONE MORPHOGENETIC PROTEIN 8B; BONE MORPHOGENETIC PROTEIN 9; BONE MORPHOGENETIC PROTEIN RECEPTOR; CYTOKINE; GROWTH DIFFERENTIATION FACTOR 1; GROWTH DIFFERENTIATION FACTOR 10; GROWTH DIFFERENTIATION FACTOR 11; GROWTH DIFFERENTIATION FACTOR 15; GROWTH DIFFERENTIATION FACTOR 3; GROWTH DIFFERENTIATION FACTOR 4; GROWTH DIFFERENTIATION FACTOR 5; GROWTH DIFFERENTIATION FACTOR 6; GROWTH DIFFERENTIATION FACTOR 9; GROWTH FACTOR; MYOSTATIN; NOGGIN; OSTEOGENIC PROTEIN 1; OSTEOGENIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; TUMOR MARKER;

APOPTOSIS; BONE METASTASIS; CANCER GROWTH; CANCER INCIDENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PERINATAL PERIOD; PROSTATE CANCER; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANIMAL; BONE TUMOR; DISEASE COURSE; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 34547580553     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (203)

1. Ahmed N., Sammons J., Carson R.J., Khokher M.A. and Hassan H.T. (2001). Effect of bone morphogenetic protein-6 on haemopoietic stem cells and cytokine production in normal human bone marrow stroma. Cell Biol. Int. 25, 429-435.
2. Andersson O., Reissmann E. and Ibanez C.F. (2006). Growth differentiation factor 11 signals through the transforming growth factor-beta receptor ALK5 to regionalize the anterior-posterior axis. EMBO Rep. 7, 831-837.
3. Aoki H., Fujii M., Imamura T., Yagi K., Takehara K., Kato M. and Miyazono K. (2001). Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J. Cell Sci. 114, 1483-1489.
4. Aono A., Hazama M., Notoya K., Taketomi S., Yamasaki H., Tsukuda R., Sasaki S. and Fujisawa Y. (1995). Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem. Biophys. Res. Commun. 210, 670-677.
5. Arora K. and Warrior R. (2001). A new Smurf in the village. Dev. Cell 1, 441-442.
6. Attisano L., Wrana J.L., Lopez-Casillas F. and Massague J. (1994). TGF-beta receptors and actions. Biochim. Biophys. Acta 1222, 71-80.
7. Autzen P., Robson C.N., Bjartell A., Malcolm A.J., Johnson M.I., Neal D.E. and Hamdy F.C. (1998). Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer 78, 1219-1223.
8. Babitt J.L., Zhang Y., Samad T.A., Xia Y., Tang J., Campagna J.A., Schneyer A.L., Woolf C.J. and Lin H.Y. (2005). Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J. Biol. Chem. 280, 29820-29827.
9. Balemans W. and Van Hul W. (2002). Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev. Biol. 250, 231-250.
10. Barnes J., Anthony C.T., Wall N. and Steiner M.S. (1995). Bone morphogenetic protein-6 expression in normal and malignant prostate. World J. Urol. 13, 337-343.
11. Beck H.N., Drahushuk K., Jacoby D.B., Higgins D. and Lein P.J. (2001). Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons. BMC Neurosci. 2, 12.
12. Bentley H., Hamdy F.C., Hart K.A., Seid J.M., Williams J.L., Johnstone O. and Russell R.G. (1992). Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 66, 1159-1163.
13. Brown M.A., Zhao Q., Baker K.A., Naik C., Chen C., Pukac L., Singh M., Tsareva T., Parice Y., Mahoney A., Roschke V., Sanyal I. and Choe S. (2005). Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J. Biol. Chem. 280, 25111-25118.
14. Brubaker K.D., Corey E., Brown L.G. and Vessella R.L. (2004). Bone morphogenetic protein signaling in prostate cancer cell lines. J. Cell Biochem. 91, 151-160.
15. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C. and Mihatsch M.J. (2000). Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578-583.
16. Buckley S., Shi W., Driscoll B., Ferrario A., Anderson K. and Warburton D. (2004). BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells. Am. J. Physiol. Lung Cell Mol. Physiol. 286, L81-86.
17. Butler S.J. and Dodd J. (2003). A role for BMP heterodimers in roof plate-mediated repulsion of commissural axons. Neuron 38, 389-401.
18. Canalis E., Economides A.N. and Gazzerro E. (2003). Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev. 24, 218-235.
19. CancerStats (2005). CancerStats Incidence UK. Cancer Research UK.
20. Celeste A.J., Iannazzi J.A., Taylor R.C., Hewick R.M., Rosen V., Wang E.A. and Wozney J.M. (1990). Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc. Natl. Acad. Sci. USA 87, 9843-9847.
21. Celeste A.J., Song J.J., Cox K., Rosen V. and Wozney J.M. (1994). Bone morphogenetic protein-9, a new member of the TGF-beta superfamily. J. Bone Min. Res. Suppl 1, S136.
22. Chang C. and Hemmati-Brivanlou A. (1999). Xenopus GDF6, a new antagonist of noggin and a partner of BMPs. Development 126, 3347-3357.
23. Chang C., Holtzman D.A., Chau S., Chickering T., Woolf E.A., Holmgren L.M., Bodorova J., Gearing D.P., Holmes W.E. and Brivanlou A.H. (2001). Twisted gastrulation can function as a BMP antagonist. Nature 410, 483-487.
24. Chen M.E., Lin S.H., Chung L.W. and Sikes R.A. (1998). Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J. Biol. Chem. 273, 17618-17625.
25. Chen X., Zankl A., Niroomand F., Liu Z., Katus H.A., Jahn L. and Tiefenbacher C. (2006). Upregulation of ID protein by growth and differentiation factor 5 (GDF5) through a smad-dependent and MAPK-independent pathway in HUVSMC. J. Mol. Cell Cardiol. 41, 26-33.
26. Chen Y.G. and Massague J. (1999). Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J. Biol. Chem. 274, 3672-3677.
27. Cheng S.K., Olale F., Bennett J.T., Brivanlou A.H. and Schier A.F. (2003). EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev. 17, 31-36.
28. Clement J.H., Marr N., Meissner A., Schwalbe M., Sebald W., Kliche K.O., Hoffken K. and Wolfl S. (2000). Bone morphogenetic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7. J. Cancer Res. Clin. Oncol. 126, 271-279.
29. Clement J.H., Raida M., Sanger J., Bicknell R., Liu J., Naumann A., Geyer A., Waldau A., Hortschansky P., Schmidt A., Hoffken K., Wolft S. and Harris A.L. (2005). Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int. J. Oncol. 27, 401-407.
30. Clement J.H., Sanger J. and Hoffken K. (1999). Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int. J. Cancer 80, 250-256.
31. Constam D.B. and Robertson E.J. (1999). Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J. Cell Biol. 144, 139-149.
32. Cui Y., Jean F., Thomas G. and Christian J.L. (1998). BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J. 17, 4735-4743.
33. Cunningham N.S., Jenkins N.A., Gilbert D.J., Copeland N.G., Reddi A.H. and Lee S.J. (1995). Growth/differentiation factor-10: a new member of the transforming growth factor-beta superfamily related to bone morphogenetic protein-3. Growth Factors 12, 99-109.
34. Dai J., Keller J., Zhang J., Lu Y., Yao Z. and Keller E.T. (2005). Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 65, 8274-8285.
35. Dai J., Kitagawa Y., Zhang J., Yao Z., Mizokami A., Cheng S., Nor J., McCauley L.K., Taichman R.S. and Keller E.T. (2004). Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res. 64, 994-999.
36. Dale K., Sattar N., Heemskerk J., Clarke J.D., Placzek M. and Dodd J. (1999). Differential patterning of ventral midline cells by axial mesoderm is regulated by BMP7 and chordin. Development 126, 397-408.
37. Daluiski A., Engstrand T., Bahamonde M.E., Gamer L.W., Agius E., Stevenson S.L., Cox K., Rosen V. and Lyons K.M. (2001). Bone morphogenetic protein-3 is a negative regulator of bone density. Nat. Genet. 27, 84-88.
38. Davidson A.J., Postlethwait J.H., Yan Y.L., Beier D.R., van Doren C., Foernzler D., Celeste A.J., Crosier K.E. and Crosier P.S. (1999). Isolation of zebrafish gdf7 and comparative genetic mapping of genes belonging to the growth/differentiation tactor 5, 6, 7 subgroup of the TGF-beta superfamily. Genome Res. 9, 121-129.
39. De Pinieux G., Flam T., Zerbib M., Taupin P., Bellahcene A., Waltregny D., Vieillefond A. and Poupon M.F. (2001). Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. J. Urol. 166, 1924-1930.
40. Deckers M.M., van Bezooijen R.L., van der Horst G., Hoogendam J., van Der Bent C., Papapoulos S.E. and Lowik C.W. (2002). Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143, 1545-1553.
41. Demers L.M., Costa L., Chinchilli V.M., Gaydos L., Curley E. and Lipton A. (1995). Biochemical markers of bone turnover in patients with metastatic bone disease. Clin. Chem. 41, 1489-1494.
42. Demers L.M., Costa L. and Lipton A. (2003). Biochemical markers and skeletal metastases. Clin. Orthop. Relat. Res. Suppl, 138-147.
43. Dionne M.S., Skarnes W.C. and Harland R.M. (2001). Mutation and analysis of Dan, the founding member of the Dan family of transforming growth factor beta antagonists. Mol. Cell Biol. 21, 636-643.
44. Dube J.L., Wang P., Elvin J., Lyons K.M., Celeste A.J. and Matzuk M.M. (1998). The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol. Endocrinol. 12, 1809-1817.
45. Ebisawa T., Tada K., Kitajima I., Tojo K., Sampath T.K., Kawabata M., Miyazono K. and Imamura T. (1999). Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J. Cell Sci. 112, 3519-3527.
46. Fainsod A., Deissler K., Yelin R., Marom K., Epstein M., Pillemer G., Steinbeisser H. and Blum M. (1997). The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. Mech. Dev. 63, 39-50.
47. Feeley B.T., Gamradt S.C., Hsu W.K., Liu N., Krenek L., Robbins P., Huard J. and Lieberman J.R. (2005). Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J. Bone Miner. Res. 20, 2189-2199.
48. Feeley B.T., Krenek L., Liu N., Hsu W.K., Gamradt S.C., Schwarz E.M., Huard J. and Lieberman J.R. (2006). Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38, 154-166.
49. Gamer L.W., Wolfman N.M., Celeste A.J., Hattersley G., Hewick R. and Rosen V. (1999). A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev. Biol. 208, 222-232.
50. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E. and Delmas P.D. (2000). Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 82, 858-864.
51. Gazzerro E., Gangji V. and Canalis E. (1998). Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J. Clin. Invest. 102, 2106-2114.
52. Gerlach-Bank L.M., Cleveland A.R. and Barald K.F. (2004). DAN directs endolymphatic sac and duct outgrowth in the avian inner ear. Dev. Dyn. 229, 219-230.
53. Glienke J., Schmitt A.O., Pilarsky C., Hinzmann B., Weiss B., Rosenthal A. and Thierauch K.H. (2000). Differential gene expression by endothelial cells in distinct angiogenic states. Eur. J. Biochem. 267, 2820-2830.
54. Greenwald J., Fischer W.H., Vale W.W. and Choe S. (1999). Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nat. Struct. Biol. 6, 18-22.
55. Grotewold L., Plum M., Dildrop R., Peters T. and Ruther U. (2001). Bambi is coexpressed with Bmp-4 during mouse embryogenesis. Mech. Dev. 100, 327-330.
56. Guo W., Gorlick R., Ladanyi M., Meyers P.A., Huvos A.G., Bertino J.R. and Healey J.H. (1999). Expression of bone morphogenetic proteins and receptors in sarcomas. Clin. Orthop. Relat. Res. 175-183.
57. Ha T.U., Segev D.L., Barbie D., Masiakos P.T., Tran T.T., Dombkowski D., Glander M., Clarke T.R., Lorenzo H.K., Donahoe P.K. and Maheswaran S. (2000). Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J. Biol. Chem. 275, 37101-37109.
58. Hallahan AR., Pritchard J.I., Chandraratna R.A., Ellenbogen R.G., Geyer J.R., Overland R.P., Strand A.D., Tapscott S.J. and Olson J.M. (2003). BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat. Med. 9, 1033-1038.
59. Hamdy F.C., Autzen P., Robinson M.C., Horne C.H., Neal D.E. and Robson C.N. (1997). Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res. 57, 4427-4431.
60. Hardwick J.C., Van Den Brink G.R., Bleuming S.A., Ballester I., Van Den Brande J.M., Keller J.J., Offerhaus G.J., Van Deventer S.J. and Peppelenbosch M.P. (2004). Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126, 111-121.
61. Harris S.E., Harris M.A., Mahy P., Wozney J., Feng J.Q. and Mundy G.R. (1994). Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24, 204-211.
62. Hashimoto O., Moore R.K. and Shimasaki S. (2005). Posttranslational processing of mouse and human BMP-15: potential implication in the determination of ovulation quota. Proc Natl. Acad. Sci. USA 102, 5426-5431.
63. Haudenschild D.R., Palmer S.M., Moseley T.A., You Z. and Reddi A.H. (2004). Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res. 64, 8276-8284.
64. Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.Y., Grinnell B.W., Richardson M.A., Topper J.N., Gimbrone M.A. Jr, Wrana J.L. and Falb D. (1997). The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89, 1165-1173.
65. Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A. and Sundan A. (2001). Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97, 516-522.
66. Horvath L.G., Henshall S.M., Kench J.G., Turner J.J., Golovsky D., Brenner P.C., O'Neill G.F., Kooner R., Stricker P.D., Grygiel J.J. and Sutherland R.L. (2004). Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 59, 234-242.
67. Hotten G., Neidhardt H., Jacobowsky B. and Pohl J. (1994). Cloning and expression of recombinant human growth/differentiation factor 5. Biochem. Biophys. Res. Commun. 204, 646-652.
68. Hsieh J.T., Wu H.C., Gleave M.E., von Eschenbach A.C. and Chung L.W. (1993). Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res. 53, 2852-2857.
69. Hsu D.R., Economides A.N., Wang X., Eimon P.M. and Harland R.M. (1998). The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol. Cell 1, 673-683.
70. Ide H., Yoshida T., Matsumoto N., Aoki K., Osada Y., Sugimura T. and Terada M. (1997). Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 57, 5022-5027.
71. Iemura S., Yamamoto T.S., Takagi C., Uchiyama H., Natsume T., Shimasaki S., Sugino H. and Ueno N. (1998). Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc. Natl. Acad. Sci. USA 95, 9337-9342.
72. Imamura T., Takase M., Nishihara A., Oeda E., Hanai J., Kawabata M. and Miyazono K. (1997). Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389, 622-626.
73. Ishisaki A., Yamato K., Hashimoto S., Nakao A., Tamaki K., Nonaka K., ten Dijke P., Sugino H. and Nishihara T. (1999). Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J. Biol. Chem. 274, 13637-13642.
74. Ishitani T., Ninomiya-Tsuji J., Nagai S., Nishita M., Meneghini M., Barker N., Waterman M., Bowerman B., Clevers H., Shibuya H. and Matsumoto K. (1999). The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 399, 798-802.
75. Israel D.I., Nove J., Kerns K.M., Kaufman R.J., Rosen V., Cox K.A. and Wazney J.M. (1996). Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 13, 291-300.
76. Itoh F., Asao H., Sugamura K., Heldin C.H., ten Dijke P. and Itoh S. (2001). Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J. 20, 4132-4142.
77. Jornvall H., Blokzijl A., ten Dijke P. and Ibanez C.F. (2001). The orphan receptor serine/threonine kinase ALK7 signals arrest of proliferation and morphological differentiation in a neuronal cell line. J. Biol. Chem. 276, 5140-5146.
78. Kakehi Y., Segawa T., Wu X.X., Kulkarni P., Dhir R. and Getzenberg R.H. (2004). Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate 59, 351-356.
79. Kaneki H., Guo R., Chen D., Yao Z., Schwarz E.M., Zhang Y.E., Boyce B.F. and Xing L. (2006). Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J. Biol. Chem. 281, 4326-4333.
80. Kim I.Y., Lee D.H., Ahn H.J., Takunaga H., Song W., Devereaux L.M., Jin D., Sampath T.K. and Morton R.A. (2000). Expression of bone marphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res. 60, 2840-2844.
81. Kim I.Y., Lee D.H., Lee D.K., Ahn H.J., Kim M.M., Kim S.J. and Morton R.A. (2004). Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23, 7651-7659.
82. Kimura N., Matsuo R., Shibuya H., Nakashima K. and Taga T. (2000). BMP2-induced apoptosis is mediated by activation at the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J. Biol. Chem. 275, 17647-17652.
83. Kirsch T., Sebald W. and Dreyer M.K. (2000). Crystal structure of the BMP-2-BRIA ectodomain complex. Nat. Struct. Biol. 7, 492-496.
84. Kitazawa S., Kitazawa R., Obayashi C. and Yamamoto T. (2005). Desmoid tumor with ossification in chest wall: possible involvement of BAMBI promoter hypermethylation in metaplastic bone formation. J. Bone Miner. Res. 20, 1472-1477.
85. Klotz L. (2000). Hormone therapy for patients with prostate carcinoma. Cancer 88, 3009-3014.
86. Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P., Correa P.E., Olson C.A., Pecquet A.L., Ventura F. and Grant R.A. (1994). Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol. Cell Biol. 14, 5961-5974.
87. Korchynskyi O., Dechering K.J., Sijbers A.M., Olijve W. and ten Dijke P. (2003). Gene array analysis of bone morphogenetic protein type I receptor-induced osteoblast differentiation. J. Bone Miner. Res. 18, 1177-1185.
88. Kowanetz M., Valcourt U., Bergstrom R., Heldin C.H. and Moustakas A. (2004). Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol. Cell Biol. 24, 4241-4254.
89. Kraunz K.S., Nelson H.H., Liu M., Wiencke J.K. and Kelsey K.T. (2005). Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer. Br. J. Cancer 93, 949-952.
90. Kretzschmar M. and Massague J. (1998). SMADs: mediators and regulators of TGF-beta signaling. Curr. Opin. Genet. Dev. 8, 103-111.
91. Kuratomi G., Komuro A., Goto K., Shinozaki M., Miyazawa K., Miyazono K. and Imamura T. (2005). NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem. J. 386, 461-470.
92. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., Thesleff I. and Itoh N. (2003). Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J. Biol. Chem. 278, 24113-24117.
93. Labrie F. (2004). Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J. Androl. 25, 305-313.
94. Langenfeld E.M., Calvano S.E., Abou-Nukta F., Lowry S.F., Amenta P. and Langenfeld J. (2003). The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24, 1445-1454.
95. Langenfeld E.M., Kong Y. and Langenfeld J. (2005). Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin. Mol. Cancer Res. 3, 679-684.
96. Lee K.J., Mendelsohn M. and Jessell T.M. (1998). Neuronal patterning by BMPs: a requirement for GDF7 in the generation of a discrete class of commissural interneurons in the mouse spinal cord. Genes Dev. 12, 3394-3407.
97. Lee S.J. (1990). Identification of a novel member (GDF-1) of the transforming growth factor-beta superfamily. Mol. Endocrinol. 4, 1034-1040.
98. Lee S.J. and McPherron A.C. (2001). Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. USA 98, 9306-9311.
99. Lee S.W., Han S.I., Kim H.H. and Lee Z.H. (2002). TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. J. Biochem. Mol. Biol. 35, 371-376.
100. Lee Y., Schwarz E., Davies M., Jo M., Gates J., Wu J., Zhang X. and Lieberman J.R. (2003). Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J. Orthop. Res. 21, 62-72.
101. Lin J., Patel S.R., Cheng X., Cho E.A., Levitan I., Ullenbruch M., Phan S.H., Park J.M. and Dressler G.R. (2005). Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat. Med. 11, 387-393.
102. Liu F., Ventura F., Doody J. and Massague J. (1995). Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol. Cell Biol. 15, 3479-3486.
103. Lopez-Coviella I., Mellott T.M., Kovacheva V.P., Berse B., Slack B.E., Zemelko V., Schnitzler A. and Blusztajn J.K. (2006). Developmental pattern of expression of BMP receptors and Smads and activation of Smad1 and Smad5 by BMP9 in mouse basal forebrain. Brain Res. 1088, 49-56.
104. Luo K., Stroschein S.L., Wang W., Chen D., Martens E., Zhou S. and Zhou Q. (1999). The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev. 13, 2196-2206.
105. Marques S., Borges A.C., Silva A.C., Freitas S., Cordenonsi M. and Belo J.A. (2004). The activity of the Nodal antagonist Cerl-2 in the mouse node is required for correct L/R body axis. Genes Dev. 18, 2342-2347.
106. Masuda H., Fukabori Y., Nakano K., Shimizu N. and Yamanaka H. (2004). Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate 59, 101-106.
107. Masuda H., Fukabori Y., Nakano K., Takezawa Y., T C.S. and Yamanaka H. (2003). Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54, 268-274.
108. Mazerbourg S. and Hsueh A.J. (2006). Genomic analyses facilitate identification of receptors and signalling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/ growth differentiation factor ligands. Hum. Reprod. Update 12, 373-383.
109. Mazerbourg S., Sangkuhl K., Luo C. W., Sudo S., Klein C. and Hsueh A. J. (2005). Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analyses. J. Biol. Chem. 280, 32122-32132.
110. McPherron A.C. and Lee S.J. (1993). GDF-3 and GDF-9: two new members of the transforming growth factor-beta superfamily containing a novel pattern of cysteines. J. Biol. Chem. 268, 3444-3449.
111. McPherron A.C., Lawler A.M. and Lee S.J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83-90.
112. McPherron A.C., Lawler A.M. and Lee S.J. (1999). Regulation of anterior/ posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat. Genet. 22, 260-264.
113. Merino R., Rodriguez-Leon J., Macias D., Ganan Y., Economides A.N. and Hurle J.M. (1999). The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb. Development 126, 5515-5522.
114. Miyazaki H., Watabe T., Kitamura T. and Miyazono K. (2004). BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23, 9326-9335.
115. Moore R.K., Otsuka F. and Shimasaki S. (2003). Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J. Biol. Chem. 278, 304-310.
116. Mori S., Yoshikawa H., Hashimoto J., Ueda T., Funai H., Kato M. and Takaoka K. (1998). Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. Bone 22, 99-105.
117. Moriguchi T., Kuroyanagi N., Yamaguchi K., Gotoh Y., Irie K., Kano T., Shirakabe K., Muro Y., Shibuya H., Matsumoto K., Nishida E. and Hagiwara M. (1996). A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J. Biol. Chem. 271, 13675-13679.
118. Moustakas A. and Heldin C.H. (2002). From mono- to oligo-Smads: the heart of the matter in TGF-beta signal transduction. Genes Dev. 16, 1867-1871.
119. Mundy G.R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593.
120. Murakami G., Watabe T., Takaoka K., Miyazono K. and Imamura T. (2003). Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol. Biol. Cell 14, 2809-2817.
121. Nacamuli R.P., Fong K.D., Lenton K.A., Song H.M., Fang T.D., Salim A. and Longaker M.T. (2005). Expression and possible mechanisms of regulation of BMP3 in rat cranial sutures. Plast. Reconstr. Surg. 116, 1353-1362.
122. Nakahara T., Tominaga K., Koseki T., Yamamoto M., Yamato K., Fukuda J. and Nishihara T. (2003). Growth/differentiation factor-5 induces growth arrest and apoptosis in mouse B lineage cells with modulation by Smad. Cell Signal 15, 181-187.
123. Nakajima Y., Yamagishi T., Hokari S. and Nakamura H. (2000). Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat. Rec. 258, 119-127.
124. Nakayama N., Han C.Y., Cam L., Lee J.I., Pretorius J., Fisher S., Rosenfeld R., Scully S., Nishinakamura R., Duryea D., Van G., Bolon B., Yokota T. and Zhang K. (2004). A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage. Development 131, 229-240.
125. Namiki M., Akiyama S., Katagiri T., Suzuki A., Ueno N., Yamaji N., Rosen V., Wozney J.M. and Suda T. (1997). A kinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts. J. Biol. Chem. 272, 22046-22052.
126. Neuhaus H., Rosen V. and Thies R.S. (1999). Heart specific expression of mouse BMP-10 a novel member of the TGF-beta superfamily. Mech. Dev. 80, 181-184.
127. Nishitoh H., Ichijo H., Kimura M., Matsumoto T., Makishima F., Yamaguchi A., Yamashita H., Enomoto S. and Miyazono K. (1996). Identification of type I and type II serine/threonine kinase receptors for growth/ differentiation factor-5. J. Biol. Chem. 271, 21345-21352.
128. Nohe A., Hassel S., Ehrlich M., Neubauer F., Sebald W., Henis Y.I. and Knaus P. (2002). The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. 277, 5330-5338.
129. Nohe A., Keating E., Knaus P. and Petersen N.O. (2004). Signal transduction of bone morphogenetic protein receptors. Cell Signal. 16, 291-299.
130. Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wolsing D.H. and Rosenbaum J.S. (1995). Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J. Biol. Chem. 270, 22522-22526.
131. Ogata T., Wozney J.M., Benezra R. and Noda M. (1993). Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helix-loop-helix molecule in osteoblast-like cells. Proc. Natl. Acad. Sci. USA 90, 9219-9222.
132. Oh S.P., Yeo C.Y., Lee Y., Schrewe H., Whitman M. and Li E. (2002). Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev. 16, 2749-2754.
133. Onichtchouk D., Chen Y.G., Dosch R., Gawantka V., Delius H., Massague J. and Niehrs C. (1999). Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401, 480-485.
134. Otsuka F., Moore R.K., Iemura S., Ueno N. and Shimasaki S. (2001). Follistatin inhibits the function of the oocyte-derived factor BMP-15. Biochem. Biophys. Res. Commun. 289, 961-966.
135. Ozkaynak E., Rueger D.C., Drier E.A., Corbett C., Ridge R.J., Sampath T.K. and Oppermann H. (1990). OP-1 cDNA encodes an osteogenic protein in the TGF-beta family. EMBO J. 9, 2085-2093.
136. Ozkaynak E., Schnegelsberg P.N., Jin D.F., Clifford G.M., Warren F.D., Drier E.A. and Oppermann H. (1992). Osteogenic protein-2. A new member of the transforming growth factor-beta superfamily expressed early in embryogenesis. J. Biol. Chem. 267, 25220-25227.
137. Pera M.F., Andrade J., Houssami S., Reubinoff B., Trounson A., Stanley E.G., Ward-van Oostwaard D. and Mummery C. (2004). Regulation of human embryonic stem cell differentiation by BMP-2 and its antagonist noggin. J. Cell Sci. 117, 1269-1280.
138. Piccolo S., Agius E., Leyns L., Bhattacharyya S., Grunz H., Bouwmeester T. and De Robertis E.M. (1999). The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature 397, 707-710.
139. Piccolo S., Sasai Y., Lu B. and De Robertis E.M. (1996). Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell 86, 589-598.
140. Pierre A., Pisselet C., Monget P., Monniaux D. and Fabre S. (2005). Testing the antagonistic effect of follistatin on BMP family members in ovine granulosa cells. Reprod. Nutr. Dev. 45, 419-425.
141. Radtke F. and Clevers H. (2005). Self-renewal and cancer of the gut: two sides of a coin. Science 307, 1904-1909.
142. Raida M., Clement J.H., Ameri K., Han C., Leek R.D. and Harris A.L. (2005). Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int. J. Oncol. 26, 1465-1470.
143. Ramoshebi L.N. and Ripamonti U. (2000). Osteogenic protein-1, a bone morphogenetic protein, induces angiogenesis in the chick chorioallantoic membrane and synergizes with basic fibroblast growth factor and transforming growth factor-beta1. Anat. Rec. 259, 97-107.
144. Re'em-Kalma Y., Lamb T. and Frank D. (1995). Competition between noggin and bone morphogenetic protein 4 activities may regulate dorsalization during Xenopus development. Proc. Natl. Acad. Sci. USA 92, 12141-12145.
145. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J. and Attisano L. (2003). Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell Biol. 23, 7230-7242.
146. Ro T.B., Holt R.U., Brenne A.T., Hjorth-Hansen H., Waage A., Hjertner O., Sundan A. and Borset M. (2004). Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23, 3024-3032.
147. Romano L.A. and Runyan R.B. (2000). Slug is an essential target of TGFbeta2 signaling in the developing chicken heart. Dev. Biol. 223, 91-102.
148. Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H., ten Dijke P., Heldin C.H. and Miyazono K. (1995). Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. USA 92, 7632-7636.
149. Ross J.J., Shimmi O., Vilmos P., Petryk A., Kim H., Gaudenz K., Hermanson S., Ekker S.C., O'Connor M.B. and Marsh J.L. (2001). Twisted gastrulation is a conserved extracellular BMP antagonist. Nature 410, 479-483.
150. Rothhammer T., Poser I., Soncin F., Bataille F., Moser M. and Bosserhoff A.K. (2005). Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res. 65, 448-456.
151. Sakuta H., Suzuki R., Takahashi H., Kato A., Shintani T., Iemura S., Yamamoto T.S., Ueno N. and Noda M. (2001). Ventroptin: a BMP-4 antagonist expressed in a double-gradient pattern in the retina. Science 293, 111-115.
152. Samad T.A., Rebbapragada A., Bell E., Zhang Y., Sidis V., Jeong S.J., Campagna J.A., Perusini S., Fabrizio D.A., Schneyer A.L., Lin H.Y., Brivanlou A.H., Attisano L. and Woolf C.J. (2005). DRAGON, a bone morphogenetic protein co-receptor. J. Biol. Chem. 280, 14122-14129.
153. Sammar M., Stricker S., Schwabe G.C., Sieber C., Hartung A., Hanke M., Oishi I., Pohl J., Minami Y., Sebald W., Mundlos S. and Knaus P. (2004). Modulation of GDF5/BRI-b signalling through interaction with the tyrosine kinase receptor Ror2. Genes Cells 9, 1227-1238.
154. Sasal Y., Lu B., Steinbelsser H. and De Robertis E.M. (1995). Regulation of neural induction by the Chd and Bmp-4 antagonistic patterning signals in Xenopus. Nature 378, 419.
155. Scherberich A., Tucker R.P., Degen M., Brown-Luedi M., Andres A.C. and Chiquet-Ehrismann R. (2005). Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene 24, 1525-1532.
156. Shi Y. and Massague J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700.
157. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., Irie K., Nishida E. and Matsumoto K. (1996). TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272, 1179-1182.
158. Shirakabe K., Yamaguchi K., Shibuya H., Irie K., Matsuda S., Moriguchi T., Gotoh Y., Matsumoto K. and Nishida E. (1997). TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J. Biol. Chem. 272, 8141-8144.
159. Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Toshiyuki S., Caminci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Wonley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A., Whiting M., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S., Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E., Jones S.J. and Marra M.A. (2002). Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. USA 99, 16899-16903.
160. Stroschein S.L., Wang W., Zhou S., Zhou Q. and Luo K. (1999). Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 286, 771-774.
161. Sudo S., Avsian-Kretchmer O., Wang L.S. and Hsueh A.J. (2004). Protein related to DAN and cerberus is a bone morphogenetic protein antagonist that participates in ovarian paracrine regulation. J. Biol. Chem. 279, 23134-23141.
162. Suzuki A., Kaneko E., Maeda J. and Ueno N. (1997). Mesoderm induction by BMP-4 and -7 heterodimers. Biochem. Biophys. Res. Commun. 232, 153-156.
163. Takase M., Imamura T., Sampath T.K., Takeda K., Ichijo H., Miyazono K. and Kawabata M. (1998). Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem. Biophys. Res. Commun. 244, 26-29.
164. Tamada H., Kitazawa R., Gohji K. and Kitazawa S. (2001). Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer. J. Bone Miner. Res. 16, 487-496.
165. ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Estevez M., Riddle D.L., Ichijo H., Heldin C.H. and Miyazono K. (1994). Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J. Biol. Chem. 269, 16985-16988.
166. Thomas R., Anderson W.A., Raman V. and Reddi A.H. (1998). Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse prostate. Prostate 37, 236-245.
167. Thomas R., True L.D., Lange P.H. and Vessella R.L. (2001). Placental bone morphogenetic protein (PLAB) gene expression in normal, premalignant and malignant human prostate: relation to tumor development and progression. Int. J. Cancer 93, 47-52.
168. Tomari K., Kumagai T., Shimizu T. and Takeda K. (2005). Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells. Int. J. Mol. Med. 15, 253-258.
169. Tsuchida K., Arai K.Y., Kuramoto Y., Yamakawa N., Hasegawa Y. and Sugino H. (2000). Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J. Biol. Chem. 275, 40788-40796.
170. Tsuji A., Hashimoto E., Ikoma T., Taniguchi T., Mori K., Nagahama M. and Matsuda Y. (1999). Inactivation of proprotein convertase, PACE4, by alpha1-antitrypsin Portland (alpha1 -PDX), a blocker of proteolytic activation of bone morphogenetic protein during embryogenesis: evidence that PACE4 is able to form an SDS-stable acyl intermediate with alpha1-PDX. J. Biochem. (Tokyo) 126, 591-603.
171. Urist M.R. (1965). Bone: formation by autoinduction. Science 150, 893-899.
172. van der Poel H.G., Hanrahan C., Zhong H. and Simons J.W. (2003). Rapamycin induces Smad activity in prostate cancer cell lines. Urol. Res. 30, 380-386.
173. Vignais M.L. (2000). Ski and SnoN: antagonistic proteins of TGFbeta signaling. Bull. Cancer 87, 135-137.
174. Wang W., Mariani F.V., Harland R.M. and Luo K. (2000). Ski represses bone morphogenic protein signaling in Xenopus and mammalian cells. Proc. Natl. Acad. Sci. USA 97, 14394-14399.
175. Wen X.Z., Akiyama Y., Baylin S.B. and Yuasa Y. (2006). Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 25, 2666-2673.
176. Wicks S.J., Haros K., Maillard M., Song L., Cohen R.E., Dijke P.T. and Chantry A. (2005). The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene 24, 8080-8084.
177. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M. and Wang E.A. (1988). Novel regulators at bone formation: molecular clones and activities. Science 242, 1528-1534.
178. Wozney J.M., Rosen V., Byrne M., Celeste A.J., Moutsatsos I. and Wang E.A. (1990). Growth factors influencing bone development. J. Cell Sci. Suppl. 13, 149-156.
179. Wrana J.L., Tran H., Attisano L., Arora K., Childs S.R., Massague J. and O'Connor M.B. (1994). Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol. Cell. Biol. 14, 944-950.
180. Wu H.C., Hsieh J.T., Gleave M.E., Brown N.M., Pathak S. and Chung L.W. (1994). Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer 57, 406-412.
181. Xu J., Kimball T.R., Lorenz J.N., Brown D.A., Bauskin A.R., Klevitsky R., Hewett T.E., Breit S.N. and Molkentin J.D. (2006). GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ. Res. 98, 342-350.
182. Xu W., Angelis K., Danielpour D., Haddad M.M., Bischof O., Campisi J., Stavnezer E. and Medrano E.E. (2000). Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc. Natl. Acad. Sci. USA 97, 5924-5929.
183. Yamaguchi K., Nagai S., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K., Ueno N., Nishida E., Shibuya H. and Matsumoto K. (1999). XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 18, 179-187.
184. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., Taniguchi T., Nishida E. and Matsumoto K. (1995). Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270, 2008-2011.
185. Yamaji N., Celeste A.J., Thies R.S., Song J.J., Bernier S.M., Goltzman D., Lyons K.M., Nove J., Rosen V. and Wozney J.M. (1994). A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BMP-4. Biochem. Biophys. Res. Commun. 205, 1944-1951.
186. Yamashita H., Shimizu A., Kato M., Nishitoh H., Ichijo H., Hanyu A., Morita I., Kimura M., Makishima F. and Miyazono K. (1997). Growth/ differentiation factor-5 induces angiogenesis in vivo. Exp. Cell Res. 235, 218-226.
187. Yang S., Zhong C., Frenkel B., Reddi A.H. and Roy-Burman P. (2005). Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res. 65, 5769-5777.
188. Yang S., Lim M., Pham L.K., Kendali S.E., Reddi A.H., Altieri D.C. and Roy-Burman P. (2006). Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways. Cancer Res. 66, 4285-4290.
189. Yeh L.C. and Lee J.C. (1999). Osteogenic protein-1 increases gene expression of vascular endothelial growth factor in primary cultures of fetal rat calvaria cells. Mol. Cell Endocrinol. 153, 113-124.
190. Yin J.J., Pollock C.B. and Kelly K. (2005). Mechanisms of cancer metastasis to the bone. Cell Res. 15, 57-62.
191. Yokouchi Y., Vogan K.J., Pearse R.V., 2nd and Tabin C.J. (1999). Antagonistic signaling by Caronte, a novel Cerberus-related gene, establishes left-right asymmetric gene expression. Cell 98, 573-583.
192. Yokoyama-Kobayashi M., Saeki M., Sekine S. and Kato S. (1997). Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. J. Biochem. (Tokyo) 122, 622-626.
193. Yoneda T. and Hiraga T. (2005). Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 328, 679-687.
194. Yoshida Y., Tanaka S., Umemori H., Minowa O., Usui M., Ikematsu N., Hosoda E., Imamura T., Kuno J., Yamashita T., Miyazono K., Noda M., Noda T. and Yamamoto T. (2000). Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103, 1085-1097.
195. Yoshida Y., von Bubnoff A., Ikematsu N., Blitz I.L., Tsuzuku J.K., Yoshida E.H., Umemori H., Miyazono K., Yamamoto T. and Cho K.W. (2003). Tob proteins enhance inhibitory Smad-receptor interactions to repress BMP signaling. Mech. Dev. 120, 629-637.
196. Yoshikawa H., Rettig W.J., Takaoka K., Alderman E., Rup B., Rosen V., Wozney J.M., Lane J.M., Huvos A.G. and Garin-Chesa P. (1994). Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody. Cancer 73, 85-91.
197. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F. and Kalluri R. (2003). BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964-968.
198. Zeisberg M., Shah A.A. and Kalluri R. (2005). Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 280, 8094-8100.
199. Zhang X., Wu J., Li X., Fu L, Gao D., Bai H. and Liu X. (2002). Effects of recombinant human bone morphogenic protein-2 and hyaluronic acid on invasion of brain glioma in vivo. Zhonghua Yi Xue Za Zhi 82, 90-93.
200. Zhu H., Kavsak P., Abdollah S., Wrana J.L. and Thomsen G.H. (1999). A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400, 687-693.
201. Zhu W., Kim J., Cheng C., Rawlins B.A., Boachie-Adjei O., Crystal R.G. and Hidaka C. (2006). Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 39, 61-71.
202. Zou H. and Niswander L. (1996). Requirement for BMP signaling in interdigital apoptosis and scale formation. Science 272, 738-741.
203. Zuzarte-Luis V., Montero J.A., Rodriguez-Leon J., Merino R., Rodriguez-Rey J.C. and Hurle J.M. (2004). A new role for BMP5 during limb development acting through the synergic activation of Smad and MAPK pathways. Dev. Biol. 272, 39-52.